| Autor: |
Gacuta KM; Department of Clinical Laboratory Diagnostics, Clinical Medical Hospital in Białystok, Białystok, Poland., Koper-Lenkiewicz OM; Department of Clinical Laboratory Diagnostics, Medical University of Białystok, Białystok, Poland., Milewska AJ; Department of Statistics and Medical Informatics, Medical University of Białystok, Białystok, Poland., Ćwiklińska-Dworakowska M; Department of General Surgical, General Hospital in Wysokie Mazowieckie, Wysokie Mazowieckie, Poland., Matowicka-Karna J; Department of Clinical Laboratory Diagnostics, Medical University of Białystok, Białystok, Poland., Kamińska J; Department of Clinical Laboratory Diagnostics, Medical University of Białystok, Białystok, Poland. |
| Jazyk: |
angličtina |
| Zdroj: |
Medical science monitor : international medical journal of experimental and clinical research [Med Sci Monit] 2023 Aug 31; Vol. 29, pp. e941109. Date of Electronic Publication: 2023 Aug 31. |
| DOI: |
10.12659/MSM.941109 |
| Abstrakt: |
BACKGROUND Thromboembolic episodes, which are largely mediated by blood platelets, are prevalent chronic complications of diabetes. The mean platelet volume (MPV) serves as a marker for in vivo platelet activation. This study aimed to assess the factors influencing MPV in 106 patients with type 2 diabetes, compared with 59 non-diabetic individuals at a single center in Poland. MATERIAL AND METHODS We performed linear regression analysis, with MPV as the dependent variable and factors such as age, sex, thrombopoiesis-influencing cytokines, blood pressure, body mass index, glycosylated hemoglobin percentage, platelet count, large platelet count, lipid profile parameters, creatinine concentration, estimated glomerular filtration rate, treatment modalities, and comorbidities as independent variables. MPV was measured using the ADVIA 2120 hematology analyzer, with a reference range of 7-12 fL. RESULTS The analysis revealed that in patients with type 2 diabetes, an increase in platelet count by 10×10³/μL resulted in a decrease in MPV by 0.05 (P<0.001), while an increase in large platelet count by 1×10³/μL led to an increase in MPV by 0.18 (P<0.001). Additionally, patients taking ß-blockers or insulin had lower MPVs by 0.77 (P=0.008) and 5.63 (P<0.001), respectively, compared with those not on these medications. CONCLUSIONS This study delineates the relationship between MPV, platelet parameters, and treatment modalities in type 2 diabetes, paving the way for further research to elucidate underlying mechanisms and potential clinical applications. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
